Detalhe da pesquisa
1.
A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration.
Eur J Neurol
; 30(6): 1727-1733, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36912432
2.
Avidity of onconeural antibodies is of clinical relevance.
Cancer Immunol Immunother
; 62(8): 1393-6, 2013 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-23733227
3.
CDR2 antigen and Yo antibodies.
Cancer Immunol Immunother
; 60(2): 283-9, 2011 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-21080165
4.
CRMP5 Antibodies-Diagnostic Challenges.
Front Neurol
; 12: 729075, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34630302
5.
Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.
Neurol Neuroimmunol Neuroinflamm
; 8(2)2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33531379
6.
Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo).
Cancer Immunol Immunother
; 59(2): 231-7, 2010 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-19680650
7.
Expression of the onconeural protein CDR1 in cerebellum and ovarian cancer.
Oncotarget
; 9(35): 23975-23986, 2018 May 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29844866
8.
Hu and Yo antibodies have heterogeneous avidity.
J Neuroimmunol
; 185(1-2): 162-7, 2007 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-17336396
9.
CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.
PLoS One
; 8(6): e66002, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-23823982